🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

91 results for “BioMarin International Limited” Clear

  1. sapropterin

    BioMarin International Limited

    Behavioral Manifestations of Lesch-Nyhan Disease

    phase 3 small molecule terminated

    1 trial

  2. sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin

    BioMarin International Limited

    Phenylketonurias

    phase 3 small molecule completed

    1 trial

  3. valoctocogene roxaparvovec

    BioMarin International Limited

    Hemophilia A

    phase 3 mab active

    5 trials

  4. 6R BH4

    BioMarin International Limited

    Kidney Disease

    phase 2 small molecule completed

    1 trial

  5. 6R-BH4

    BioMarin International Limited

    Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  6. 6R-BH4

    BioMarin International Limited

    Isolated Systolic Hypertension

    phase 2 small molecule terminated

    1 trial

  7. 6R-BH4 (sapropterin dihydrochloride)

    BioMarin International Limited

    Hypertension

    phase 2 small molecule completed

    1 trial

  8. Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

    BioMarin International Limited

    Achondroplasia

    phase 2 small molecule active

    1 trial

  9. BMN 044 IV 6 mg/kg

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  10. BMN 110

    BioMarin International Limited

    Mucopolysaccharidosis IVA

    phase 2 small molecule terminated

    3 trials

  11. BMN 110

    BioMarin International Limited

    MPS IV A

    phase 2 small molecule terminated

    2 trials

  12. BMN 165 (rAvPAL-PEG)

    BioMarin International Limited

    Phenylketonuria

    phase 2 mab completed

    1 trial

  13. BMN 190

    BioMarin International Limited

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    2 trials

  14. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin International Limited

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  15. BMN 307

    BioMarin International Limited

    Phenylketonuria (PKU)

    phase 2 small molecule active

    1 trial

  16. BMN 351

    BioMarin International Limited

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  17. BMN 351

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  18. BMN 701

    BioMarin International Limited

    Pompe Disease

    phase 2 mab completed

    2 trials

  19. Dose 1 of BMN 331

    BioMarin International Limited

    Hereditary Angioedema

    phase 2 gene therapy active

    1 trial

  20. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  21. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  22. PRO044 SC

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  23. PRO044 SC 6 mg/kg

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  24. PRO045, 0.15 mg/kg/week

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources